Published in Respir Med on March 11, 2011
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One (2013) 0.83
Differential changes in quality of life components over 5 years in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis (2015) 0.81
COPD: maximization of bronchodilation. Multidiscip Respir Med (2014) 0.80
Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung (2013) 0.80
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
Indacaterol in chronic obstructive pulmonary disease: an update for clinicians. Ther Adv Chronic Dis (2012) 0.78
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis (2014) 0.77
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol (2005) 2.59
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (2010) 2.27
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Drosophila MUS312 interacts with the nucleotide excision repair endonuclease MEI-9 to generate meiotic crossovers. Mol Cell (2002) 1.79
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med (2010) 1.64
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc (2007) 1.56
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med (2011) 1.41
Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.35
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med (2011) 1.31
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther (2010) 1.30
Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest (2006) 1.30
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med (2008) 1.21
Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.19
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin (2009) 1.15
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology (2012) 1.14
Measuring the effects of COPD on the patient. Respir Med (2005) 1.13
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res (2010) 1.12
Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med (2010) 1.11
Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol (2003) 1.02
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res (2011) 1.01
Inflammation in COPD: implications for management. Am J Med (2012) 1.00
Recent advances in dyspnea. Chest (2015) 0.99
Splenic marginal zone lymphoma. Blood Rev (2005) 0.97
Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2011) 0.97
The European reference condition concept: A scientific and technical approach to identify minimally-impacted river ecosystems. Sci Total Environ (2012) 0.96
Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther (2011) 0.95
Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest (2004) 0.94
Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.94
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther (2010) 0.92
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis (2010) 0.90
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med (2011) 0.89
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol (2010) 0.88
Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD (2012) 0.88
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis (2011) 0.87
Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies. Clin Drug Investig (2011) 0.87
Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health (2012) 0.87
Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J (2011) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol (2007) 0.85
Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med (2012) 0.84
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol (2008) 0.84
Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients. Radiother Oncol (2002) 0.83
Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer. Radiother Oncol (2012) 0.82
Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Allergy Asthma Proc (2005) 0.81
Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD (2011) 0.81
Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. Radiother Oncol (2011) 0.81
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk Lymphoma (2013) 0.81
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J (2013) 0.81
Updates to the guidelines for the diagnosis and management of multiple myeloma. Br J Haematol (2014) 0.79
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. Allergol Int (2010) 0.79
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Haematologica (2012) 0.79
Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials (2011) 0.78
Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis (2011) 0.78
Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest (2009) 0.78
Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest (2008) 0.77
Prospective Use of Descriptors of Dyspnea to Diagnose Common Respiratory Diseases. Chest (2015) 0.77
Muscarinic receptor antagonist-induced lenticular opacity in rats. Toxicol Sci (2002) 0.77
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. J Asthma (2008) 0.77
Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc (2004) 0.77
Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc (2003) 0.76
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest (2014) 0.76
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. Respir Med (2010) 0.76
Are you fluent in the language of dyspnea? Chest (2008) 0.75
More is better once again! J Cardiopulm Rehabil (2005) 0.75
Is physical activity anti-inflammatory on the airways? Thorax (2007) 0.75
Hit the dyspnea target! J Cardiopulm Rehabil (2003) 0.75
Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genet Cytogenet (2004) 0.75
Response. Chest (2014) 0.75
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. Br J Haematol (2013) 0.75
Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study. Acta Haematol (2006) 0.75
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years. Br J Haematol (2011) 0.75
It's about time--directing our attention toward modifying the course of COPD. Respir Med (2008) 0.75
The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin Pediatr (Phila) (2002) 0.75